Lidocaine 1% Fresenius Kabi (Lidocaine Hydrochloride Monohydrate)

Lidocaine works by blocking voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This prevents the generation and propagation of action potentials, thereby interrupting nerve signal transmission and producing reversible loss of sensation in the area where it is applied.

The appropriate dose of lidocaine 1% is determined by the prescribing clinician based on the intended route, patient characteristics, and the specific procedure. Dosage calculations consider factors such as body weight, maximum allowable dose, and the site of administration.

Safety data for lidocaine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Clinicians are advised to assess each case individually and follow local regulatory guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration of action, making it suitable for many short‑ to medium‑duration procedures. Compared with ester‑type agents such as procaine, lidocaine has a lower risk of allergic reactions and a more predictable pharmacokinetic profile.

Lidocaine 1% should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Do not freeze. Inspect the container for any signs of contamination before use.

Lidocaine can be administered via epidural, intramuscular or intravenous injection, depending on the clinical indication. The solution is typically drawn into a sterile syringe and injected into the target tissue or vascular compartment by a qualified healthcare professional.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias, central nervous system toxicity such as seizures, and methemoglobinemia. Prompt recognition of these events and immediate medical intervention are essential to mitigate harm.

Lidocaine should be avoided in individuals with known hypersensitivity to amide‑type local anesthetics, patients with severe heart block or uncontrolled cardiac conduction disorders, and in cases where the maximum recommended dose cannot be safely respected.